Hedge Fund - Broadfin Capital

Although the average hedge fund has been struggling to beat broader market benchmarks in recent years, the hedge fund industry as a whole has been constantly growing.

At Insider Monkey, we focus mainly on the 13F filings of around 730 hedge funds and other institutional investors, in order to identify trading opportunities and benefit from them.

Some bright minds of the finance world believe that shareholder activism has surged in recent years because of increased market efficiency.

Most hedge funds and other money managers tracked by Insider Monkey have not submitted their 13F filings for the September quarter just yet.

The battle between Broadfin Capital and the Board of Cardica, Inc. (NASDAQ:CRDC) is heating up.

According to a recent 13G form filed with the Securities and Exchange Commission Kevin Kotler's (pictured) Broadfin Capital has added 1.18 million shares to its stake in Nevro Corp (NYSE:NVRO) taking...

Kevin Kotler's healthcare fund Broadfin Capital, the top performing fund in our database this year based on the calculated returns of its public equity positions in companies with a $1 billion+ market...

Both Antares Pharma Inc (NASDAQ:ATRS) and Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) recently had their names attached to 13G forms, as two hedge funds raised their holdings in the companies.

As disclosed in a Schedule 13G filing with the U.S. Securities and Exchange Commission, Kevin Kotler’s Broadfin Capital holds an ownership stake of 1.66 million shares in Advaxis Inc.